Other TNFI includes golimumab (a humanized anti‐TNF‐α monoclonal antibody that was generated and affinity matured in an in vivo system) and certolizumab pegol (a pegylated humanized Fab' fragment of an anti‐TNF monoclonal antibody with a high affinity for TNF‐α), both of which have not been studied in relation to periodontitis. This evidence concerns the gene TNF and periodontitis.